Novo Nordisk, a leading pharmaceutical company, is taking legal action against two compounding pharmacies for producing counterfeit versions of its popular weight-loss and diabetes drug, Ozempic. The company has filed a total of 12 lawsuits against medical spas, weight-loss clinics, and compounding pharmacies engaged in selling counterfeit drugs. Novo Nordisk's rival, Eli Lilly & Co., has also filed similar legal actions against businesses selling counterfeit versions of its blockbuster diabetes drug, Mounjaro.
Highlighting serious concerns about patient safety, Novo Nordisk has discovered troubling levels of unknown impurities and lower potency in the compounded products. Jason Brett, the Executive Director of Medical Affairs for Novo's US affiliate, expressed concerns that patients' health could potentially be at risk due to these factors.
One of the compounding pharmacies facing lawsuits from both Novo Nordisk and Eli Lilly is Wells Pharmacy Network. Novo Nordisk has found that Wells Pharmacy Network's products contain a peptide called BPC-157, which has been deemed unsafe by the US Food and Drug Administration (FDA). The FDA issued a warning about BPC-157 in September, stating that it might take legal action against compounding pharmacies for using the substance in their products. The World Anti-Doping Agency has also banned the use of BPC-157, citing insufficient research on its effects.
The FDA's oversight of compounded drugs is not as extensive as that of traditional prescription drugs. However, the FDA has cautioned consumers about safety complaints associated with compounded semaglutide—the active ingredient in Novo Nordisk's Ozempic and Wegovy. The FDA advises patients to opt for approved drugs when available rather than rely on compounded drugs.
In addition to Wells Pharmacy Network, Novo Nordisk is also suing Brooksville Pharmaceuticals, a compounding pharmacy located in Florida. These legal actions are part of the company's ongoing efforts to protect patients from potentially harmful counterfeit drugs and ensure the safety and quality of its medications.
By pursuing legal action against compounding pharmacies, Novo Nordisk aims to reinforce the importance of adhering to established regulations and maintaining rigorous safety standards in the pharmaceutical industry. The company's commitment to patient well-being and the maintenance of its reputation as a trusted provider of high-quality medications remain at the forefront of these legal actions.